MANASH

Exploiting the MSP-AMPK pathway for amelioration of NASH

Coordinatore	UNIVERSITEIT MAASTRICHT    more  Organization address address: Minderbroedersberg 4-6 city: MAASTRICHT postcode: 6200 MD contact info Titolo: Dr. Nome: Dietbert Cognome: Neumann Email: send email Telefono: 31433881851 Fax: 31433884574
Nazionalità Coordinatore	Netherlands [NL]
Totale costo	183˙469 €
EC contributo	183˙469 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2012-IIF
Funding Scheme	MC-IIF
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-03-01   -   2015-02-28

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITEIT MAASTRICHT  Organization address address: Minderbroedersberg 4-6 city: MAASTRICHT postcode: 6200 MD contact info Titolo: Dr. Nome: Dietbert Cognome: Neumann Email: send email Telefono: 31433881851 Fax: 31433884574	NL (MAASTRICHT)	coordinator	183˙469.80

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'BACKGROUND Non–alcoholic steatohepatitis (NASH) is the hepatic event of the metabolic syndrome and is characterized by steatosis and inflammation. Although our understanding of the disease mechanisms has progressed, the therapy options for treatment of NASH remain poor. AMP-activated protein kinase (AMPK) is an important integrator of signals managing energy balance and acts as a protective response to energy stress during metabolic deregulations. Pharmacologic AMPK activation is a well-established treatment strategy against the metabolic syndrome and has been reported to ameliorate steatosis, but accumulating evidence suggests that global AMPK activation is undesirable, especially because of affecting appetite. Macrophage-stimulating protein (MSP) is a multifunctional serum factor secreted from liver cells and a ligand for Recepteur d'origine nantais (RON) receptor tyrosine kinase to initiate downstream signaling pathways in an autocrine fashion. MSP exhibits anti-inflammatory properties on macrophages. Interestingly, MSP-deficient mice on normal diet develop hepatic steatosis. However, the role of MSP in normal liver metabolism and metabolic syndrome remained underexplored. Previous studies by the applicant demonstrated MSP as a negative regulator of hepatic gluconeogenesis and of inflammatory responses, both via AMPK activation.

HYPOTHESIS MSP-mediated activation of AMPK is an effective treatment option against NASH.

OBJECTIVES 1) Investigate the molecular mechanism and metabolic/anti-inflammatory action of MSP-mediated AMPK activation in cultured hepatocytes and macrophages. 2) Stimulate the MSP/AMPK pathway in liver to assess the potential of ameliorating NASH in relevant mouse models.

DELIVERABLES 1) Identification of novel upstream regulators of AMPK downstream of MSP/RON. 2) Appraisal of MSP for possible treatment of NASH in humans.'